Brawn Biotech (Small Cap) Share Target 2024, 2025 To 2039
|
Brawn Biotech Limited |
|||
|
Price: ₹24.47 | ||
| 52 Week Low: ₹14.63 52 Week High: ₹27.82 |
|||
| Market Capital: 6.36 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Brawn Biotech Share Price Target For 2024
- 1.1.1: Brawn Biotech Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Brawn Biotech Share Price Target For 2025
- 1.2.1: Brawn Biotech Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Brawn Biotech Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Brawn Biotech Financial Performance
- 3.0.1: Is Brawn Biotech A Good Buy For Long Term?
To predict the Brawn Biotech's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Brawn Biotech Share Price Target For 2024
The line chart displays the monthly closing prices of Brawn Biotech with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Brawn Biotech shares in 2024, see the table below.
Brawn Biotech Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 26.17 (+6.94%) | Price Action: 07 May 2024 High |
| 2024 Target 2 | 25.9 (+5.84%) | Fibonacci Extension Level 23.60% |
| 2024 Target 1 | 25.45 (+4%) | Price Action: 11 Dec 2023 High |
| Current Price | 24.47 | Brawn Biotech's share price as of 26 Dec 2024 |
| Stop Loss 1 | 24.05 (-1.72%) | Price Action: 24 Jul 2024 Low |
| Stop Loss 2 | 23.8 (-2.74%) | Price Action: Dec 2019 Low |
| Stop Loss 3 | 23.52 (-3.89%) | Price Action: 06 Mar 2024 High |
Short-Term Technical Outlook
Current Technical Position: Brawn Biotech is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹21.45 serves as the nearest technical reference point.
Historical Returns: 3-month: +27.12% | 6-month: -6.57% | 1-year: +11.74%
Brawn Biotech Share Price Target For 2025
The line chart displays the monthly closing prices of Brawn Biotech with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Brawn Biotech shares in 2025, see the table below.
Brawn Biotech Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 33.99 (+38.9%) | Price Action: Chart |
| 2025 Target 2 | 33.36 (+36.33%) | Price Action: Chart |
| 2025 Target 1 | 33.03 (+34.97%) | Fibonacci Extension Level 64.90% |
| Current Price | 24.47 | Brawn Biotech's share price as of 26 Dec 2024 |
| Stop Loss 1 | 22.5 (-8.06%) | Price Action: Feb 2020 Low |
| Stop Loss 2 | 22.26 (-9.03%) | Price Action: 11 Nov 2024 Low |
| Stop Loss 3 | 22.02 (-10.02%) | Price Action: 19 Sep 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Brawn Biotech is currently trading at 74.6% of its 52-week range (₹14.63 - ₹27.82).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +11.74% | 3-year: +7.09% | 5-year: -3.85%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Brawn Biotech Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹24.47 | ||
| 2024 | ₹19.66 | -19.65% | ₹19.95 |
| 2025 | ₹19.85 | +0.96% | ₹21.54 |
| 2026 | ₹18.98 | -4.38% | ₹20.78 |
| 2027 | ₹19.13 | +0.79% | ₹20.03 |
| 2028 | ₹17.59 | -8.05% | ₹19.81 |
| 2029 | ₹16.92 | -3.8% | ₹19.26 |
| 2030 | ₹17.00 | +0.47% | ₹18.52 |
| 2031 | ₹16.18 | -4.82% | ₹17.77 |
| 2032 | ₹16.22 | +0.24% | ₹17.02 |
| 2033 | ₹14.83 | -8.56% | ₹16.78 |
| 2034 | ₹14.18 | -4.38% | ₹16.23 |
| 2035 | ₹14.15 | -0.21% | ₹15.51 |
| 2036 | ₹13.37 | -5.51% | ₹14.76 |
| 2037 | ₹22.21 | +66.11% | ₹23.12 |
| 2038 | ₹21.12 | -4.9% | ₹23.12 |
| 2039 | ₹21.00 | -0.56% | ₹23.19 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Brawn Biotech Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 6.36 Crore | Market valuation of Brawn Biotech's shares. |
| Revenue (TTM) | 16.49 Crore | Total revenue generated by Brawn Biotech over the past twelve months. |
| Net Income (TTM) | -1.54 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -9.34% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +12.91% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+17.91% | Change in revenue compared to the previous quarter. |
Is Brawn Biotech A Good Buy For Long Term?
Brawn Biotech, a small-cap stock with a market capitalization of 6.36 Crore, presents a complex picture for long-term investors. While it boasts a revenue of 16.49 Crore (TTM), a significant net loss of 1.54 Crore and a negative profit margin of -9.34% raise serious concerns. Despite positive 12-month returns (27.75%), the past 5-year performance (-45.52%) indicates substantial risk. Considering this volatility and consistent losses, Brawn Biotech is not a good buy for the long term at present. Further investigation into the reasons behind its recurring losses is crucial before any investment consideration.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
